Effects of cisplatin on photosensitizer-mediated photodynamic therapy in breast tumor-bearing nude mice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveThis study aimed to evaluate the potential effects of cisplatin on photodynamic therapy (PDT) in breast cancer using abreast tumor-bearing mouse model. MethodsIn this study, breast tumor (experimental mammary tumour-6 cell)-bearing nude mice were used as experimentalanimals. Photolon® (photosensitizer, 2.5 mg/kg body weight [BW]) was injected intraperitoneally; after 2 hours,the tumors were irradiated (660 nm, 80 J/cm2) using a diode laser tool. Cisplatin (3 mg/kg BW) was injectedintraperitoneally 1 hour before the Photolon® injection. ResultsTumor volume increased over time in the control group and was not different from that in the cisplatin group. Inthe PDT group, the tumor volume increased on day 3, but not on day 7. In the cisplatin+PDT group, tumor volumeincreased on day 3 but decreased on day 7. There was no significant difference in the levels of thiobarbituric acidreactive substance (TBARS) in tumor tissues between the control and cisplatin groups. The levels of TBARS in thecisplatin+PDT group were higher (47%) than those in the PDT group. Analysis of tumor tissue transcriptomes showedthat the expression of genes related to the inflammatory response including CL and XCL genes increased, while thatof Fn1 decreased in the cisplatin+PDT group compared with the PDT group. ConclusionThese results suggest that cisplatin enhances the therapeutic effect of PDT in a breast tumor-bearing mouse model. However, further clinical studies involving patients with breast cancer is needed.
Abstract
ObjectiveThis study aimed to evaluate the potential effects of cisplatin on photodynamic therapy (PDT) in breast cancer using abreast tumor-bearing mouse model. MethodsIn this study, breast tumor (experimental mammary tumour-6 cell)-bearing nude mice were used as experimentalanimals. Photolon® (photosensitizer, 2.5 mg/kg body weight [BW]) was injected intraperitoneally; after 2 hours,the tumors were irradiated (660 nm, 80 J/cm2) using a diode laser tool. Cisplatin (3 mg/kg BW) was injectedintraperitoneally 1 hour before the Photolon® injection. ResultsTumor volume increased over time in the control group and was not different from that in the cisplatin group. Inthe PDT group, the tumor volume increased on day 3, but not on day 7. In the cisplatin+PDT group, tumor volumeincreased on day 3 but decreased on day 7. There was no significant difference in the levels of thiobarbituric acidreactive substance (TBARS) in tumor tissues between the control and cisplatin groups. The levels of TBARS in thecisplatin+PDT group were higher (47%) than those in the PDT group. Analysis of tumor tissue transcriptomes showedthat the expression of genes related to the inflammatory response including CL and XCL genes increased, while thatof Fn1 decreased in the cisplatin+PDT group compared with the PDT group. ConclusionThese results suggest that cisplatin enhances the therapeutic effect of PDT in a breast tumor-bearing mouse model. However, further clinical studies involving patients with breast cancer is needed.
참고문헌 (32)
- McGuire A, "Effects of age on the detection and management of breast cancer", Cancers(Basel), 7, pp.908~929 (2015)
- Mangla B, "Combination of natural agent with synthetic drug for the breast cancer therapy", Int J Drug Dev Res, 10, pp.22~26 (2018)
- Agostinis P, "Photodynamic therapy of cancer : an update", CA Cancer J Clin, 61, pp.250~281 (2011)
- Silva JN, "Photodynamic therapies : principles and present medical applications", Biomed Mater Eng, 16, pp.S147~54 (2006)
- O’Connor AE, "Porphyrin and nonporphyrin photosensitizers in oncology : preclinical and clinical advances in photodynamic therapy", Photochem Photobiol, 85, pp.1053~1074 (2009)
- Chin WW, "Fluorescence imaging and phototoxicity effects of new formulation of chlorin e6-polyvinylpyrrolidone", J Photochem Photobiol B, 84, pp.103~110 (2006)
- Petrov P, "Photolon an agent for photodynamic diagnosis and therapy : non-clinical and clinical experience", Acta Bio-Optica et Informatica Medica, 10, pp.6~7 (2004)
- Ge R, "An in vitro and in vivo study of combination therapy with Photogem®-mediated photodynamic therapy and cisplatin on mouse cancer cells(CT-26)", Photomed Laser Surg, 29, pp.155~160 (2011)
- Lim HS, "Development and optimization of a diode laser for photodynamic therapy", Laser Ther, 20, pp.195~203 (2011)
- Beyer W, "Systems for light application and dosimetry in photodynamic therapy", J Photochem Photobiol B, 36, pp.153~156 (1996)
- Kelland L, "The resurgence of platinum-based cancer chemotherapy", Nat Rev Cancer, 7, pp.573~584 (2007)
- Peddi P, "Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer : a retrospective review", Clin Med Insights Oncol, 9, pp.1~7 (2015)
- Galluzzi L, "Molecular mechanisms of cisplatin resistance", Oncogene, 31, pp.1869~1883 (2012)
- Hartmann JT, "Toxicity of platinum compounds", Expert Opin Pharmacother, 4, pp.889~901 (2003)
- Stathopoulos GP, "Cisplatin : process and future", J BUON, 18, pp.564~569 (2013)
- Ali S, "Study of low doses cisplatin synergistic effect on photodynamic outcome of aluminum phythalocyanine on soft tissue sarcoma(RD)cell line", Photodiagn Photodyn Ther, 12, pp.146~149 (2015)
- Wei XQ, "Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells", Asian Pac J Cancer Prev, 14, pp.3023~3028 (2013)
- Huang da W, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources", Nat Protoc, 4, pp.44~57 (2009)
- Berg K, "Lysosomes as photochemical targets", Int J Cancer, 59, pp.814~822 (1994)
- Chen B, "Tumor vascular permeabilization by vasculartargeting photosensitization : effects, mechanism, and therapeutic implications", Clin Cancer Res, 12, pp.917~923 (2006)
- Johnsson A, "Pharmacokinetics and tissue distribution of cisplatin in nude mice : platinum levels and cisplatin-DNA adducts", Cancer Chemother Pharmacol, 37, pp.23~31 (1995)
- Chekulayeva LV, "Hydrogen peroxide, superoxide, and hydroxyl radicals are involved in the phototoxic action of hematoporphyrin derivative against tumor cells", J Environ Pathol Toxicol Oncol, 25, pp.51~77 (2006)
- Brozovic A, "The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin", Crit Rev Toxicol, 40, pp.347~359 (2010)
- Korbelik M, "PDT-associated host response and its role in the therapy outcome", Lasers Surg Med, 38, pp.500~508 (2006)
- Xu LL, "Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro", J Leukoc Biol, 60, pp.365~371 (1996)
- Opdenakker G, "Human monocyte chemotactic protein-3(MCP-3) : molecular cloning of the cDNA and comparison with other chemokines", Biochem Biophys Res Commun, 191, pp.535~542 (1993)
- Jia GQ, "Distinct expression and function of the novel mouse chemokine monocyte chemotactic protein-5 in lung allergic inflammation", J Exp Med, 184, pp.1939~1951 (1996)
- Wolpe SD, "Identification and characterization of macrophage inflammatory protein 2", Proc Natl Acad Sci U S A, 86, pp.612~616 (1989)
- Persson T, "Expression of the neutrophil-activating CXC chemokine ENA-78", CXCL5 by human eosinophils, 2003, pp.33, 531~537
- Luster AD, "Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins", Nature, 315, pp.672~676 (1985)
- Anestakis D, "Mechanisms and applications of interleukins in cancer immunotherapy", Int J Mol Sci, 16, pp.1691~1710 (2015)
- Pankov R, "Fibronectin at a glance", J Cell Sci, 115, pp.3861~3863 (2002)